High expression of ZRF1 or BRD4 was also associated with poor survival of patients with breast cancer, colon cancer, Ewing sarcoma, glioma, melanoma, myeloma, or renal cancer (Additional file 1: Fig. S12). Here, BRD4 is linked to plasma cell myeloma.